Please login to the form below

Not currently logged in
Email:
Password:

Merck licenses University of Edinburgh research tool

Gains access to novel disease progression technology
Merck

Merck KGaA has acquired access to a pioneering research tool from The University of Edinburgh for the study of early stage disease progression.

Developed by the university's commercialisation arm, Edinburgh Research & Innovation, the technology uses a fluorescent compound to tag peptides and so make them visible as disease reporters.

The tool, which has been designed not interfere to with the peptides' natural state, makes their identification easier under a microscope and so allows researchers to better track disease onset and behaviour.

Dr Marc Vendrell, principal investigator of The University of Edinburgh's School of Clinical Sciences team, said: “One of the main advantages of our technology is that it can be broadly applied to almost all peptides, having a global impact in biomedicine.

“This means that our technology will improve our understanding of disease at many different levels, from cancer to the regeneration of tissues or the progression of inflammatory diseases.”

Currently subject of a patent application, the peptide technology was funded by a Marie Curie Career Integration Grant from the EU Commission, and worked on with academic partners at the University of Barcelona and the University of Manchester.

Merck's Udit Batra, chief executive of Merck Life Science, said: “At Merck, we are always looking for innovative ideas to enhance our customers' research efforts.

“This compound from the University of Edinburgh offers researchers a way to fluorescently label peptides that has minimal interference with peptide structure.

“This will enable biological discovery and complement our portfolio of chemical biology tools.”

Article by
Rebecca Clifford

1st November 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health is an integrated communications agency designed for and inspired by the ever-changing face of healthcare. In London, we...

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...

Infographics